Patents by Inventor Florian Anton Martin Huber

Florian Anton Martin Huber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200223865
    Abstract: The present invention relates to a process for synthesis of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol abbreviated THIP, having the INN name gaboxadol, starting from pyrrolidin-2-one. The process comprises a new direct process to obtain the intermediate dimethyl 5-hydroxy-3,6-dihydropyridine-1,4(2H)-dicarboxylate or the intermediate diethyl 5-hydroxy-3,6-dihydropyridine-1,4(2H)-dicarboxylate.
    Type: Application
    Filed: March 24, 2020
    Publication date: July 16, 2020
    Inventors: Carla De Faveri, Florian Anton Martin Huber
  • Patent number: 10626123
    Abstract: The present invention relates to a process for synthesis of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol abbreviated THIP, having the INN name gaboxadol, starting from pyrrolidin-2-one. The process comprises a new direct process to obtain the intermediate dimethyl 5-hydroxy-3,6-dihydropyridine-1,4(2H)-5 dicarboxylate or the intermediate diethyl 5-hydroxy-3,6-dihydropyridine-1,4(2H)-dicarboxylate.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: April 21, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Carla De Faveri, Florian Anton Martin Huber
  • Patent number: 10385020
    Abstract: Methods are provided for the synthesis of key intermediates for the synthesis of Argatroban monohydrate, ethyl (2R,4R)-1-[(2S)-2-amino-5-[[imino(nitroamino)methyl]amino]-1-oxopentyl]-4-methylpiperidine-2-carboxylate compounded with HCl. Such intermediates are also provided.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: August 20, 2019
    Assignee: LUNDBECK PHARMACEUTICALS ITALY S.P.A.
    Inventors: Mariano Stivanello, Florian Anton Martin Huber, Antonio Ricci
  • Patent number: 10329264
    Abstract: This invention relates to a novel chemical process for the synthesis of N?-benzyl-5-methylisoxazole-3-carbohydrazide (Isocarboxazid) which comprises reacting 5-methyl-3-isoxazole carboxylic acid ester with benzylhydrazine or a salt thereof in an aprotic organic solvent and in the presence of an organic base.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: June 25, 2019
    Assignee: Lundbeck Pharmaceuticals Italy S.P.A.
    Inventors: Carla De Faveri, Florian Anton Martin Huber, Nicola Antolini
  • Publication number: 20180258041
    Abstract: Methods are provided for the synthesis of key intermediates for the synthesis of Argatroban monohydrate, ethyl (2R,4R)-1-[(2S)-2-amino-5-[[imino(nitroamino)methyl]amino]-1-oxopentyl]-4-methylpiperidine-2-carboxylate compounded with HCl. Such intermediates are also provided.
    Type: Application
    Filed: May 11, 2018
    Publication date: September 13, 2018
    Applicant: LUNDBECK PHARMACEUTICALS ITALY S.p.A.
    Inventors: Mariano Stivanello, Florian Anton Martin HUBER, Antonio RICCI
  • Publication number: 20180215722
    Abstract: This invention relates to a novel chemical process for the synthesis of N?-benzyl-5-methylisoxazole-3-carbohydrazide (Isocarboxazid) which comprises reacting 5-methyl-3-isoxazole carboxylic acid ester with benzylhydrazine or a salt thereof in an aprotic organic solvent and in the presence of an organic base.
    Type: Application
    Filed: July 27, 2016
    Publication date: August 2, 2018
    Inventors: Carla De Faveri, Florian Anton Martin Huber, Nicola Antolini
  • Patent number: 9994526
    Abstract: Methods are provided for the synthesis of key intermediates for the synthesis of Argatroban monohydrate, ethyl (2R,4R)-1-[(2S)-2-amino-5-[[imino(nitroamino)methyl]amino]-1-oxopentyl]-4-methylpiperidine-2-carboxylate compounded with HCl. Such intermediates are also provided.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: June 12, 2018
    Assignee: LUNDBECK PHARMACEUTICALS ITALY S.p.A.
    Inventors: Mariano Stivanello, Florian Anton Martin Huber, Antonio Ricci
  • Patent number: 9975850
    Abstract: The present invention relates to the preparation of N-(2-(6-fluoro-1H-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine (Compound I), INN-name idalopirdine, and pharmaceutically acceptable salts thereof:
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: May 22, 2018
    Assignee: H. LUNDBECK A/S
    Inventors: Mikkel Fog Jacobsen, Florian Anton Martin Huber
  • Publication number: 20180065984
    Abstract: The present invention relates to a process for synthesis of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol abbreviated THIP, having the INN name gaboxadol, starting from pyrrolidin-2-one. The process comprises a new direct process to obtain the intermediate dimethyl 5-hydroxy-3,6-dihydropyridine-1,4(2H)-5 dicarboxylate or the intermediate diethyl 5-hydroxy-3,6-dihydropyridine-1,4(2H)-dicarboxylate.
    Type: Application
    Filed: March 22, 2016
    Publication date: March 8, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Carla De Faveri, Florian Anton Martin Huber
  • Publication number: 20170291874
    Abstract: The present invention relates to the preparation of N-(2-(6-fluoro-1H-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine (Compound I), INN-name idalopirdine, and pharmaceutically acceptable salts thereof:
    Type: Application
    Filed: April 6, 2017
    Publication date: October 12, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Mikkel Fog Jacobsen, Florian Anton Martin Huber
  • Publication number: 20160347711
    Abstract: Methods are provided for the synthesis of key intermediates for the synthesis of Argatroban monohydrate, ethyl (2R,4R)-1-[(2S)-2-amino-5-[[imino(nitroamino)methyl]amino]-1-oxopentyl]-4-methylpiperidine-2-carboxylate compounded with HCl. Such intermediates are also provided.
    Type: Application
    Filed: August 12, 2016
    Publication date: December 1, 2016
    Applicant: LUNDBECK PHARMACEUTICALS ITALY S.p.A.
    Inventors: Mariano Stivanello, Florian Anton Martin HUBER, Antonio RICCI
  • Patent number: 8912360
    Abstract: Methods for preparing Ritodrine hydrochloride are provided. Also provided is non-hygroscopic, crystalline, polymorphic Ritodrine hydrochloride of Form I.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: December 16, 2014
    Assignee: Lundbeck Pharmaceuticals Italy S.p.A.
    Inventors: Jacopo Zanon, Giovanna Libralon, Carla De Faveri, Florian Anton Martin Huber
  • Patent number: 8754217
    Abstract: The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride dihydrate.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: June 17, 2014
    Assignee: H. Lundbeck A/S
    Inventors: Heidi Lopez de Diego, Carla De Faveri, Florian Anton Martin Huber
  • Publication number: 20140155608
    Abstract: The present invention relates to a new process for producing naltrexone [17-(cyclopropylmethyl)-4,5?-epoxy-3,14-dihydroxy-morphinan-6-one] from noroxymorphone [4,5-?-epoxy-3,14-dihydroxy-morphinan-6-one] by alkylation with a cyclopropylmethyl halide.
    Type: Application
    Filed: May 2, 2013
    Publication date: June 5, 2014
    Inventors: Carla De Faveri, Mariano Stivanello, Florian Anton Martin Huber
  • Publication number: 20140088310
    Abstract: Methods are provided for the synthesis of key intermediates for the synthesis of Argatroban monohydrate, ethyl (2R,4R)-1-[(2S)-2-amino-5-[[imino(nitroamino)methyl]amino]-1-oxopentyl]-4-methylpiperidine-2-carboxylate compounded with HCl. Such intermediates are also provided.
    Type: Application
    Filed: March 26, 2012
    Publication date: March 27, 2014
    Applicant: LUNDBECK PHARMACEUTICALS ITALY S.P.A.
    Inventors: Mariano Stivanello, Florian Anton Martin Huber, Antonio Ricci
  • Publication number: 20130338365
    Abstract: The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride dehydrate.
    Type: Application
    Filed: June 25, 2013
    Publication date: December 19, 2013
    Inventors: Heidi Lopez de DIEGO, Carla de FAVERI, Florian Anton Martin HUBER
  • Patent number: 8580963
    Abstract: The present invention relates to an improved process for producing naltrexone[17-(cyclopropylmethyl)-4,5?-epoxy-3,14-dihydroxy-morphinan-6-one] from noroxymorphone[4,5-?-epoxy-3,14-dihydroxy-morphinan-6-one] by alkylation with a cyclopropylmethyl halide.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: November 12, 2013
    Assignee: H. Lundbeck A/S
    Inventors: Carla De Faveri, Florian Anton Martin Huber, Mariano Stivanello
  • Patent number: 8530495
    Abstract: The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride dihydrate.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: September 10, 2013
    Assignees: H. Lundbeck A/S, Bioei Therapies Corp
    Inventors: Heidi Lopez de Diego, Carla de Faveri, Florian Anton Martin Huber
  • Patent number: 8436209
    Abstract: The present invention relates to a process for manufacturing N-Formyl-1-amino-3,5-dimethyladamantane, an intermediate product in the overall process of producing 1-Amino-3,5-dimethyladamantane hydrochloride (Memantine). Therein, the process comprises the following steps: (a) reacting 1,3-dimethyladamantane with an acid mixture comprising concentrated sulfuric acid and concentrated nitric acid, wherein 1 to 6 volume parts of sulfuric acid (measured in ml) are used per weight part of 1,3-dimethyladamantane (measured in g); (b) reacting the solution from step (a) with an amount of formamide varying from 1 to 5 molar equivalents per mole of deprotonated 1,3-dimethyladamantane from step (a) to obtain N-Formyl-1-amino-3,5-dimethyladamantane. In step (b), the molar ratio of total acid, i.e. the molar amount of sulfuric acid and the molar amount of nitric acid taken together versus the molar amount of formamide is at least 1.5 and that the temperature is at least 50° C.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: May 7, 2013
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Florian Anton Martin Huber, Giorgio Gallo, Carla De Faveri
  • Publication number: 20120116085
    Abstract: The present invention relates to an improved process for producing naltrexone[17-(cyclopropylmethyl)-4,5?-epoxy-3,14-dihydroxy-morphinan-6-one] from noroxymorphone[4,5-?-epoxy-3,14-dihydroxy-morphinan-6-one] by alkylation with a cyclopropylmethyl halide.
    Type: Application
    Filed: November 2, 2011
    Publication date: May 10, 2012
    Applicant: H. Lundbeck A/S
    Inventors: Carla De Faveri, Florian Anton Martin Huber, Mariano Stivanello